{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:07:40Z","timestamp":1770484060379,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T00:00:00Z","timestamp":1336694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10147-012-0414-8","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:36:27Z","timestamp":1336610187000},"page":"531-538","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of bone metastases before the onset of pain"],"prefix":"10.1007","volume":"18","author":[{"given":"Luis","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,11]]},"reference":[{"key":"414_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"414_CR2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736\u20131740","journal-title":"Br J Cancer"},{"key":"414_CR3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer (Phila) 88:1082\u20131090","journal-title":"Cancer (Phila)"},{"key":"414_CR4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"414_CR5","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer (Phila) 100:2613\u20132621","journal-title":"Cancer (Phila)"},{"key":"414_CR6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (Phila) 110:1860\u20131867","journal-title":"Cancer (Phila)"},{"key":"414_CR7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD et al (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"},{"key":"414_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y et al (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42:164\u2013175","journal-title":"Med Care"},{"key":"414_CR9","first-page":"15","volume":"3","author":"MA Sabino","year":"2005","unstructured":"Sabino MA, Mantyh PW (2005) Pathophysiology of bone cancer pain. J Support Oncol 3:15\u201324","journal-title":"J Support Oncol"},{"key":"414_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","volume":"53","author":"A Heidenreich","year":"2008","unstructured":"Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68\u201380","journal-title":"Eur Urol"},{"key":"414_CR11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420\u2013432","journal-title":"Ann Oncol"},{"key":"414_CR12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Poznak Van","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221\u20131227","journal-title":"J Clin Oncol"},{"key":"414_CR13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","volume":"4","author":"F Marinis De","year":"2009","unstructured":"De Marinis F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4:1280\u20131288","journal-title":"J Thorac Oncol"},{"key":"414_CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.addr.2004.12.014","volume":"57","author":"CM Bagi","year":"2005","unstructured":"Bagi CM (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57:995\u20131010","journal-title":"Adv Drug Deliv Rev"},{"key":"414_CR15","unstructured":"Amgen Inc. (2010) Xgeva (denosumab) injection (product insert). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/125320s007lbl.pdf . Accessed Sep 2011"},{"key":"414_CR16","unstructured":"Amgen Inc. (2011) Xgeva 120\u00a0mg solution for injection (summary of product characteristics). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf . Accessed Sep 2011"},{"key":"414_CR17","doi-asserted-by":"crossref","unstructured":"Shore ND, Smith MR, Jievaltas M et al (2011) Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior SRE and baseline pain. J Clin Oncol 29:(abstr 4533)","DOI":"10.1200\/jco.2011.29.15_suppl.4533"},{"key":"414_CR18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer (Phila) 98:1735\u20131744","journal-title":"Cancer (Phila)"},{"key":"414_CR19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"414_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3816\/SCT.2007.n.016","volume":"4","author":"A Kretzschmar","year":"2007","unstructured":"Kretzschmar A, Wiege T, Al-Batran SE et al (2007) Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1\u00a0year. Support Cancer Ther 4:203\u2013210","journal-title":"Support Cancer Ther"},{"key":"414_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","volume":"33","author":"J Gralow","year":"2007","unstructured":"Gralow J, Tripathy D (2007) Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manag 33:462\u2013472","journal-title":"J Pain Symptom Manag"},{"key":"414_CR22","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"414_CR23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL, Yanagihara RH, Wood AJ et al (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687\u2013695","journal-title":"Oncologist"},{"key":"414_CR24","unstructured":"Cleeland C, Patrick D, Fallowfield L et al (2010) Effects of denosumab vs. zoledronic acid on pain in patients with advanced cancer and bone metastases: an integrated analysis of 3 pivotal trials. Presented at 35th ESMO Congress, Milan (abstract 1248P)"},{"key":"414_CR25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","volume":"76","author":"F Saad","year":"2010","unstructured":"Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175\u20131181","journal-title":"Urology"},{"key":"414_CR26","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"A Stopeck","year":"2010","unstructured":"Stopeck A, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"414_CR27","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"414_CR28","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989\u20131999","journal-title":"Lancet"},{"key":"414_CR29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","volume":"12","author":"GJ Morgan","year":"2011","unstructured":"Morgan GJ, Child JA, Gregory WM et al (2011) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 12:743\u2013752","journal-title":"Lancet Oncol"},{"key":"414_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/TCRM.S2707","volume":"4","author":"TJ Polascik","year":"2008","unstructured":"Polascik TJ, Mouraviev V (2008) Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 4:261\u2013268","journal-title":"Ther Clin Risk Manag"},{"key":"414_CR31","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","volume":"13","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Van Poznak CH, Wiliams T et al (2008) Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13:911\u2013920","journal-title":"Oncologist"},{"key":"414_CR32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836","journal-title":"J Bone Miner Res"},{"key":"414_CR33","unstructured":"Lipton A, Siena S, Rader M et al (2010) Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Ann Oncol 21:viii380 (abstr 1249P)"},{"key":"414_CR34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117\u2013120","journal-title":"Ann Oncol"},{"key":"414_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"key":"414_CR36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdn630","volume":"20","author":"T Wyngaert Van den","year":"2009","unstructured":"Van den Wyngaert T, Claeys T, Huizing MT et al (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331\u2013336","journal-title":"Ann Oncol"},{"key":"414_CR37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","volume":"6","author":"V Hirsh","year":"2004","unstructured":"Hirsh V, Tchekmedyian NS, Rosen LS et al (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6:170\u2013174","journal-title":"Clin Lung Cancer"},{"key":"414_CR38","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","volume":"113","author":"HT Hatoum","year":"2008","unstructured":"Hatoum HT, Lin SJ, Smith MR et al (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer (Phila) 113:1438\u20131445","journal-title":"Cancer (Phila)"},{"key":"414_CR39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/07357907.2010.483508","volume":"28","author":"NS Tchekmedyian","year":"2010","unstructured":"Tchekmedyian NS, Chen YM, Saad F (2010) Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest 28:849\u2013855","journal-title":"Cancer Invest"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0414-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-012-0414-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0414-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:01:09Z","timestamp":1561726869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-012-0414-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1007\/s10147-012-0414-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,11]]}}}